CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Medical Device Manufacturers Association

Medical Device Manufacturers Association is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clintrak

Clintrak is a Bohemia, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Transit Resources Inc

Transit Resources Inc is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DecisionLine Clinical Research

DecisionLine Clinical Research is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frontage Laboratories

Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United States, China and other countries.